Pharmacology of ACE Inhibitors

Introduction/Overview

Angiotensin-converting enzyme (ACE) inhibitors represent a cornerstone class of therapeutic agents in cardiovascular and renal medicine. Their development followed the elucidation of the renin-angiotensin-aldosterone system (RAAS), a critical hormonal pathway regulating blood pressure, fluid balance, and electrolyte homeostasis. By inhibiting the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, these drugs produce a cascade of beneficial hemodynamic and tissue effects. Since the introduction of captopril in the early 1980s, ACE inhibitors have become first-line therapy for multiple conditions, including hypertension, heart failure, and diabetic nephropathy, fundamentally altering the management and prognosis of these diseases. Their clinical importance is underscored by extensive outcome data from large-scale randomized controlled trials demonstrating reductions in morbidity and mortality.

Learning Objectives

• Describe the molecular mechanism of action of ACE inhibitors within the context of the renin-angiotensin-aldosterone and kinin-kallikrein systems.
• Compare and contrast the pharmacokinetic properties of different ACE inhibitors, including absorption, metabolism, elimination, and dosing considerations.
• List the primary approved clinical indications for ACE inhibitor therapy and explain the pathophysiological rationale for their use in each condition.
• Identify the common and serious adverse effects associated with ACE inhibitors, including angioedema, cough, and hyperkalemia, and describe their underlying mechanisms.
• Analyze major drug interactions and special population considerations, such as use in renal impairment, pregnancy, and the elderly.

Classification

ACE inhibitors are classified primarily according to their chemical structure, which influences binding affinity to the enzyme’s active site, pharmacokinetic profile, and, to some extent, potency. This chemical classification is broadly based on the ligand that binds to the zinc ion at the active site of ACE.

Chemical Classification

• Sulfhydryl-containing Agents: This group is characterized by a sulfhydryl (-SH) moiety that coordinates with the zinc ion of ACE. Captopril is the sole widely used member of this class. Its sulfhydryl group is associated with certain side effects, such as skin rash and taste disturbance, and may contribute to antioxidant properties.
• Dicarboxylate-containing Agents: This is the largest and most commonly prescribed group. It includes enalapril, lisinopril, ramipril, quinapril, perindopril, and trandolapril. These agents possess a carboxyl group that binds to the zinc ion. They are generally prodrugs (except lisinopril), requiring esterification in the liver to form the active diacid metabolite, which confers a longer duration of action.
• Phosphonate-containing Agents: Fosinopril is the principal agent in this category, containing a phosphinyl group as the zinc-binding ligand. This unique structure is associated with balanced dual hepatic and renal elimination, which may be advantageous in patients with renal or hepatic dysfunction.

Clinically, ACE inhibitors can also be categorized based on their pharmacokinetic behavior, particularly their half-life and whether they are administered as prodrugs. Lisinopril is a notable exception as an active drug with a long half-life, while others like enalapril and ramipril are prodrugs converted to active metabolites.

Mechanism of Action

The primary pharmacodynamic effect of ACE inhibitors is competitive inhibition of the angiotensin-converting enzyme. This enzyme, a dipeptidyl carboxypeptidase, plays a pivotal role in two key physiological systems: the pressor renin-angiotensin-aldosterone system (RAAS) and the depressor kinin-kallikrein system.

Inhibition of the Renin-Angiotensin-Aldosterone System

ACE catalyzes the conversion of the inactive decapeptide angiotensin I to the potent octapeptide vasoconstrictor angiotensin II. By blocking this conversion, ACE inhibitors lead to a reduction in circulating and tissue levels of angiotensin II. The consequences of this inhibition are multifactorial:

• Vasodilation: Reduced angiotensin II levels diminish its direct vasoconstrictive effect on arteriolar smooth muscle, leading to a decrease in systemic vascular resistance and afterload.
• Reduced Aldosterone Secretion: Angiotensin II is a primary stimulus for aldosterone release from the adrenal cortex. Lower aldosterone levels decrease sodium and water reabsorption in the distal nephron, promoting natriuresis and diuresis, which reduces plasma volume and preload.
• Inhibition of Sympathetic Outflow: Angiotensin II facilitates norepinephrine release from sympathetic nerve endings and stimulates central sympathetic activity. ACE inhibition attenuates this effect, contributing to a reduction in heart rate and cardiac output.
• Reduction of Vascular and Cardiac Hypertrophy: Angiotensin II acts as a growth factor, promoting hypertrophy of cardiac myocytes and hyperplasia of vascular smooth muscle cells. Chronic ACE inhibition can reverse or prevent these structural changes, an effect considered independent of blood pressure reduction.

Potentiation of the Kinin-Kallikrein System

ACE is identical to kininase II, the enzyme responsible for the degradation of vasoactive kinins, most notably bradykinin. Inhibition of ACE therefore leads to the accumulation of bradykinin and related kinins. Bradykinin acts on endothelial B₂ receptors to stimulate the release of nitric oxide, prostacyclin, and endothelium-derived hyperpolarizing factor, resulting in potent vasodilation. This mechanism is believed to contribute significantly to the therapeutic vasodilatory effects of ACE inhibitors. However, bradykinin accumulation is also implicated in the pathogenesis of the characteristic dry cough and angioedema associated with this drug class.

Cellular and Tissue Effects

Beyond hemodynamic alterations, ACE inhibitors exert important tissue-protective effects. The reduction in angiotensin II decreases the expression of pro-fibrotic and pro-inflammatory mediators such as transforming growth factor-beta (TGF-β) and plasminogen activator inhibitor-1 (PAI-1). In the kidney, this results in reduced glomerular capillary pressure and decreased proteinuria, providing renoprotection. In the cardiovascular system, it attenuates adverse remodeling following myocardial infarction and slows the progression of atherosclerosis.

Pharmacokinetics

The pharmacokinetic profiles of ACE inhibitors vary considerably, influencing their dosing frequency, onset of action, and suitability for specific patient populations. Key parameters include bioavailability, protein binding, metabolism, route of elimination, and half-life.

Absorption

Oral bioavailability ranges widely among ACE inhibitors. Captopril has a bioavailability of approximately 60-75%, but this is reduced by 30-40% when taken with food, necessitating administration on an empty stomach. Most dicarboxylate-containing prodrugs (e.g., enalapril, ramipril, quinapril) have higher bioavailabilities, typically between 25% and 70%, with less pronounced food effects. Lisinopril, an active drug, has a lower and more variable bioavailability of about 25-30%. Absorption generally occurs in the proximal small intestine.

Distribution

ACE inhibitors are distributed widely throughout the body. Volume of distribution values are generally moderate. Most ACE inhibitors, except captopril and lisinopril, are highly bound to plasma proteins (>90%). Tissue penetration is significant, with some agents like ramipril and perindopril exhibiting high tissue ACE affinity, which may correlate with prolonged enzyme inhibition at tissue sites. The extent of distribution into the central nervous system is limited but may be sufficient to influence central sympathetic outflow.

Metabolism

Metabolic pathways differ by agent. Captopril undergoes minimal hepatic metabolism, with some conversion to disulfide dimers. The majority of ACE inhibitors (enalapril, ramipril, quinapril, perindopril, trandolapril, fosinopril) are administered as ester prodrugs to improve oral bioavailability. These prodrugs are hydrolyzed primarily in the liver and, to a lesser extent, in the intestinal wall and plasma, to their active diacid forms. Lisinopril is not metabolized and is excreted unchanged. The active metabolites are responsible for the pharmacological effect and typically have longer half-lives than the parent prodrugs.

Excretion

The route of elimination is a critical factor in dosing adjustments for renal impairment. Most ACE inhibitors and their active metabolites are eliminated predominantly by the kidneys via glomerular filtration and, for some, active tubular secretion. This includes captopril, lisinopril, enalaprilat, and ramiprilat. Consequently, their half-lives are prolonged, and doses must be reduced in patients with chronic kidney disease. Fosinoprilat is an exception, with balanced elimination via both renal and hepatic pathways, requiring less frequent dose adjustment in renal failure. The terminal elimination half-life of the active moiety dictates dosing frequency: captopril (2-3 hours, requiring 2-3 times daily dosing), enalaprilat (11 hours, once or twice daily), and lisinopril/ramiprilat (12+ hours, once daily).

Pharmacokinetic Parameters Summary

Key pharmacokinetic values are illustrative: Captopril reaches a peak plasma concentration (C_max) in about 1 hour, with a half-life (t_1/2) of 2-3 hours. Enalapril is converted to enalaprilat, which has a t_1/2 of 11 hours. Lisinopril has a t_1/2 of 12 hours, and ramiprilat has a t_1/2 of 13-17 hours. The relationship between dose, clearance, and steady-state concentration can be described by the principle: Steady-State Plasma Concentration = (Bioavailability × Dose) ÷ (Clearance × Dosing Interval).

Therapeutic Uses/Clinical Applications

ACE inhibitors are indicated for a spectrum of cardiovascular and renal disorders, supported by robust evidence from clinical trials demonstrating benefits in mortality, hospitalizations, and disease progression.

Approved Indications

• Hypertension: ACE inhibitors are recommended as first-line therapy for hypertension, particularly in patients with compelling indications such as diabetes, chronic kidney disease, or heart failure. They are effective as monotherapy and in combination with thiazide diuretics or calcium channel blockers. Their antihypertensive effect correlates with pre-treatment plasma renin activity.
• Heart Failure with Reduced Ejection Fraction (HFrEF): In all stages of symptomatic HFrEF, ACE inhibitors improve symptoms, functional class, and reduce mortality and hospitalizations. They mitigate adverse ventricular remodeling, decrease neurohormonal activation, and reduce preload and afterload. Therapy is initiated at low doses and titrated upward to evidence-based target doses.
• Post-Myocardial Infarction: Administration within 24 hours of an acute myocardial infarction, particularly anterior wall infarction or infarction with left ventricular dysfunction, improves survival and reduces the incidence of subsequent heart failure. This benefit is attributed to the attenuation of ventricular dilation and remodeling.
• Diabetic and Non-Diabetic Chronic Kidney Disease (CKD): In patients with diabetic nephropathy, evidenced by proteinuria (>300 mg/day), ACE inhibitors slow the progression to end-stage renal disease independent of their blood pressure-lowering effect. This renoprotective effect extends to many forms of non-diabetic proteinuric CKD.
• Secondary Stroke Prevention: Certain ACE inhibitors, such as perindopril, often in combination with indapamide, are indicated to reduce the risk of recurrent stroke in patients with a history of cerebrovascular disease.
• High Cardiovascular Risk: Ramipril is approved for the reduction of risk for myocardial infarction, stroke, and death in patients aged 55 years or older with established atherosclerotic disease, diabetes, or other cardiovascular risk factors.

Off-Label Uses

Common off-label applications include the treatment of systolic hypertension in the elderly, the management of left ventricular hypertrophy, and the reduction of proteinuria in various glomerulopathies. They are sometimes used in the management of scleroderma renal crisis. Their use in heart failure with preserved ejection fraction (HFpEF) remains controversial, with current evidence not strongly supporting a mortality benefit.

Adverse Effects

While generally well-tolerated, ACE inhibitors are associated with a distinct profile of adverse effects, ranging from common and benign to rare and life-threatening.

Common Side Effects

• Dry, Persistent Cough: Reported in 5-20% of patients, this is a class effect believed to be mediated by accumulation of bradykinin and substance P in the respiratory tract. It is more common in women and typically resolves within 1-4 weeks of discontinuation.
• Hypotension: First-dose hypotension can occur, particularly in patients who are volume-depleted, on high-dose diuretics, or have high-renin states (e.g., heart failure). A small initial dose is recommended to mitigate this risk.
• Hyperkalemia: By reducing aldosterone secretion, ACE inhibitors decrease renal potassium excretion. The risk is heightened in patients with renal impairment, diabetes, or those concurrently using potassium-sparing diuretics, potassium supplements, or NSAIDs.
• Renal Impairment: A reversible rise in serum creatinine (up to 30% above baseline) may occur due to the reduction in glomerular filtration pressure, especially in patients with bilateral renal artery stenosis, severe heart failure, or volume depletion. This typically stabilizes and does not necessitate discontinuation unless it is progressive.
• Dizziness, Headache, and Fatigue: These are often related to the magnitude of blood pressure reduction and tend to diminish with continued therapy.

Serious/Rare Adverse Reactions

• Angioedema: A potentially life-threatening condition characterized by non-pitting edema of the face, lips, tongue, larynx, and pharynx. It occurs in approximately 0.1-0.7% of patients, with a higher incidence in Black patients. The mechanism involves bradykinin-mediated increased vascular permeability. It requires immediate, permanent discontinuation of the ACE inhibitor.
• Fetotoxicity: ACE inhibitors are contraindicated in pregnancy due to risks of fetal malformations (e.g., skull hypoplasia, pulmonary hypoplasia), oligohydramnios, and neonatal renal failure, particularly during the second and third trimesters.
• Neutropenia/Agranulocytosis: This was a concern with high-dose captopril in early studies but is exceedingly rare with current dosing regimens and other agents in the class.
• Hepatotoxicity: A rare idiosyncratic reaction, presenting as cholestatic jaundice, which resolves upon drug withdrawal.

Black Box Warnings

All ACE inhibitors carry a black box warning regarding use during pregnancy, as described above. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus when used in the second and third trimesters.

Drug Interactions

Pharmacodynamic and pharmacokinetic interactions with ACE inhibitors are clinically significant and require careful management.

Major Drug-Drug Interactions

• Diuretics: Concurrent use, especially with high-dose or potent loop diuretics, potentiates the risk of first-dose hypotension and severe volume depletion. It is often recommended to withhold diuretics for 24-48 hours before initiating ACE inhibitor therapy or to initiate the ACE inhibitor at a very low dose.
• Potassium-Sparing Diuretics & Potassium Supplements: The combination with amiloride, triamterene, spironolactone, or eplerenone significantly increases the risk of hyperkalemia due to synergistic reduction in renal potassium excretion.
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): NSAIDs can attenuate the antihypertensive and heart failure benefits of ACE inhibitors by inhibiting prostaglandin-mediated vasodilation. They also impair renal blood flow autoregulation, increasing the risk of acute kidney injury and hyperkalemia.
• Lithium: ACE inhibitors reduce renal clearance of lithium, potentially leading to lithium toxicity. Serum lithium levels require close monitoring if co-administration is necessary.
• Angiotensin Receptor Blockers (ARBs) & Aliskiren: Dual RAAS blockade with an ACE inhibitor and an ARB or direct renin inhibitor is generally not recommended due to increased risks of hyperkalemia, hypotension, and renal dysfunction without clear additional benefit in most populations.
• Antidiabetic Agents: ACE inhibitors may enhance the hypoglycemic effect of insulin and sulfonylureas, possibly by improving insulin sensitivity, necessitating blood glucose monitoring.

Contraindications

Absolute contraindications include a history of angioedema related to previous ACE inhibitor therapy, bilateral renal artery stenosis (or stenosis in a solitary kidney), and pregnancy. Relative contraindications include significant hyperkalemia (>5.0 mmol/L), severe renal impairment (e.g., eGFR <30 mL/min/1.73m²) without dose adjustment, and aortic stenosis or hypertrophic obstructive cardiomyopathy, where afterload reduction may be detrimental.

Special Considerations

Pregnancy and Lactation

ACE inhibitors are classified as Pregnancy Category D (positive evidence of human fetal risk). They are contraindicated in all trimesters due to the risk of fetotoxicity, but the risk is highest and most characteristic in the second and third trimesters, causing oligohydramnios, fetal renal tubular dysplasia, and hypocalvaria. Women of childbearing potential should be advised of these risks. ACE inhibitors are generally considered compatible with breastfeeding, as only minimal amounts are excreted into breast milk; however, captopril and enalapril are often preferred in this setting due to more extensive safety data.

Pediatric and Geriatric Considerations

In pediatric patients, ACE inhibitors are used primarily for hypertension and proteinuric kidney diseases. Dosing is based on weight or body surface area, starting at the low end of the range. Close monitoring of blood pressure, renal function, and potassium is essential. In geriatric patients, age-related declines in renal function and lean body mass necessitate caution. The “start low, go slow” adage applies, often initiating therapy at half the usual adult dose. Orthostatic hypotension is a greater concern due to potential blunting of baroreceptor reflexes.

Renal Impairment

Renal function must be assessed before and during ACE inhibitor therapy. In patients with chronic kidney disease, ACE inhibitors are renoprotective but require dose adjustment based on estimated glomerular filtration rate (eGFR). For most agents (except fosinopril), the dosing interval is lengthened or the dose is reduced when eGFR falls below 30-40 mL/min/1.73m². A rise in serum creatinine of up to 30% within the first 4 weeks is acceptable and often indicates effective glomerular pressure reduction. A more significant or progressive rise warrants evaluation for renal artery stenosis or volume depletion.

Hepatic Impairment

Dose adjustment is generally not required for mild to moderate hepatic impairment. However, for prodrug ACE inhibitors (e.g., enalapril, ramipril), impaired hepatic esterase activity could theoretically reduce conversion to the active form, potentially blunting efficacy. This is rarely of clinical significance. In severe hepatic disease with associated ascites and high-renin state, the risk of hypotension and renal impairment is increased, warranting cautious initiation.

Race and Genetics

Black patients with hypertension tend to have a lower-renin profile and may exhibit a smaller average blood pressure reduction with ACE inhibitor monotherapy compared to white patients. However, they derive similar benefits in heart failure and kidney disease. The incidence of angioedema is higher in Black patients. Genetic polymorphisms in ACE, bradykinin receptors, or other pathways may influence individual therapeutic response and side effect profiles, but routine genetic testing is not currently standard practice.

Summary/Key Points

• ACE inhibitors exert their primary effect by inhibiting the conversion of angiotensin I to angiotensin II and by potentiating the effects of bradykinin, leading to vasodilation, reduced aldosterone, and beneficial tissue effects.
• They are classified chemically into sulfhydryl-, dicarboxylate-, and phosphonate-containing groups, which influence pharmacokinetics and some adverse effect profiles.
• Key pharmacokinetic differences exist, particularly regarding prodrug activation (most agents) versus active drug (lisinopril) and primary route of elimination (renal for most, dual for fosinopril), dictating dosing frequency and need for adjustment in renal impairment.
• Major approved indications include hypertension, heart failure with reduced ejection fraction, post-myocardial infarction, diabetic and non-diabetic proteinuric chronic kidney disease, and secondary cardiovascular risk reduction.
• The most common adverse effects are dry cough and hyperkalemia. Serious adverse effects include angioedema (bradykinin-mediated) and fetotoxicity. A black box warning exists for use in pregnancy.
• Significant drug interactions occur with diuretics (hypotension), potassium-sparing agents (hyperkalemia), NSAIDs (reduced efficacy, renal risk), and lithium (toxicity).
• Special population considerations mandate dose reduction in renal impairment, avoidance in pregnancy, cautious “start low” dosing in the elderly, and awareness of differential efficacy and angioedema risk in Black patients.

Clinical Pearls

• Monitor serum potassium and creatinine within 1-2 weeks of initiation or dose escalation, and periodically thereafter.
• A dry, persistent cough may develop weeks to months after starting therapy and is a common reason for discontinuation; switching to an angiotensin receptor blocker (ARB) is often effective as ARBs do not affect bradykinin metabolism.
• In heart failure, titrate the dose to the evidence-based target, not just until symptoms improve, to achieve maximal mortality benefit.
• Do not discontinue therapy for a modest, stable rise in creatinine (≤30%); instead, evaluate for volume depletion or other causes.
• Always inquire about a history of facial or throat swelling before prescribing an ACE inhibitor, and educate patients to recognize the symptoms of angioedema.

References

1. Opie LH, Gersh BJ. Drugs for the Heart. 9th ed. Philadelphia: Elsevier; 2021.
2. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
3. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
4. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
5. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
7. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.